Black Diamond Therapeutics Inc logo

BDTX - Black Diamond Therapeutics Inc News Story

$24.51 -0.3  -1.3%

Last Trade - 6:24pm

Sector
Healthcare
Size
Mid Cap
Market Cap £651.3m
Enterprise Value £422.6m
Revenue £n/a
Position in Universe 2934th / 6854

Black Diamond Therapeutics Announces Appointment of Oncology Clinical Development Veteran Dr. Kapil Dhingra to Board of Directors

Wed 20th January, 2021 12:45pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210120:nGNX928h71&default-theme=true


CAMBRIDGE, Mass. and NEW YORK, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Black Diamond
Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company
pioneering the discovery and development of small molecule, tumor-agnostic
therapies, today announced the appointment of Dr. Kapil Dhingra to its Board
of Directors. Dr. Dhingra has more than 30 years’ experience in oncology
clinical research and drug development, including as Vice President, Head of
the Oncology Disease Biology Leadership Team and Head of Oncology Clinical
Development at Hoffmann-La Roche (“Roche”). He has served as a clinical
and strategic advisor to Black Diamond since 2017.

“I am delighted to welcome Kapil to the Black Diamond Board of Directors,”
said Robert A. Ingram, Chairman of the Board of Directors of Black Diamond
Therapeutics. “Kapil brings substantial oncology drug development
experience, and his insights and perspectives will be of tremendous benefit as
Black Diamond pursues its vision of becoming a leader in the field of
precision medicine.”

“We are excited to welcome Kapil to our Board at this important time for
Black Diamond,” said David M. Epstein, Ph.D., President and Chief Executive
Officer of Black Diamond Therapeutics. “Kapil is a recognized leader in the
biopharmaceutical industry and has been an important advisor to the Company
for several years. His clinical development expertise will be critical as we
advance BDTX-189, BDTX-1535, and our broader pipeline of MasterKey inhibitor
product candidates through clinical development.”

“Black Diamond has the potential to transform the landscape of oncology
therapeutics, and I am thrilled to join Black Diamond’s Board,” said Dr.
Dhingra. “I look forward to working alongside my fellow Board members and
Black Diamond’s dynamic leadership team to advance innovative precision
oncology solutions for patients who lack sufficient targeted treatment
options.”

Dr. Dhingra is an accomplished medical oncologist and pharmaceutical executive
with a proven track record in academic research, patient care, and drug
development. From 1999 to 2008, Dr. Dhingra served at Roche, including as Vice
President, Head of the Oncology Disease Biology Leadership Team and Head of
Oncology Clinical Development, during which he led numerous drug approvals,
including Herceptin(®), Tarceva(®), and Avastin(®). Prior to joining Roche,
he worked in the oncology clinical development group at Eli Lilly and Company.

Dr. Dhingra has served as a faculty member at The University of Texas M.D.
Anderson Cancer Center, Indiana University School of Medicine, and Memorial
Sloan Kettering Cancer Center. Dr. Dhingra is currently a member of the Boards
of Directors of Replimune, Inc., Five Prime Therapeutics, Inc., Autolus
Therapeutics plc, and Median Technologies, and he has previously served on the
boards of several biotech companies acquired by major pharmaceutical
companies. Dr. Dhingra founded KAPital Consulting, LLC in 2008, a company
dedicated to helping biotechnology, pharmaceutical, and diagnostic companies
realize the clinical and commercial advances in oncology. Dr. Dhingra obtained
his M.B.B.S. degree from the All India Institute of Medical Sciences in New
Delhi, India. He completed his residency in internal medicine at Lincoln
Medical and Mental Health Center and New York Medical College and completed
his fellowship in hematology and oncology at Emory University School of
Medicine.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a precision oncology medicine company pioneering
the discovery of small molecule, tumor-agnostic therapies. Black Diamond
targets undrugged mutations in patients with genetically defined cancers.
Black Diamond is built upon a deep understanding of cancer genetics, protein
structure and function, and medicinal chemistry. The Company’s proprietary
technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is
designed to allow Black Diamond to analyze population-level genetic sequencing
data to identify oncogenic mutations that promote cancer across tumor types,
group these mutations into families, and develop a single small molecule
therapy in a tumor-agnostic manner that targets a specific family of
mutations. Black Diamond was founded by David M. Epstein, Ph.D. and Elizabeth
Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began
building the MAP platform and chemistry discovery engine. For more
information, please visit www.blackdiamondtherapeutics.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding future plans
or expectations for the Mutation-Allostery-Pharmacology platform, including
the potential of the Company’s strategy and product candidates, and the
continued development and advancement of the Company’s pipeline, including
BDTX-189, BDTX-1535 and early-stage pipeline programs. Any forward-looking
statements in this statement are based on management’s current expectations
of future events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. Risks that contribute
to the uncertain nature of the forward-looking statements include: the
success, cost, and timing of the Company’s product candidate development
activities and planned clinical trials, the Company’s ability to execute on
its strategy, regulatory developments in the United States, the Company’s
ability to fund operations, and the impact that the current COVID-19 pandemic
will have on the Company’s clinical trials, supply chain, and operations, as
well as those risks and uncertainties set forth in its 2019 annual report on
Form 10-K filed with the United States Securities and Exchange Commission and
its other filings filed with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press release
speak only as of the date on which they were made. The Company undertakes no
obligation to update such statements to reflect events that occur or
circumstances that exist after the date on which they were made.

Contacts:

For Investors:
Natalie Wildenradt
investors@bdtherapeutics.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtherapeutics.com

(https://www.globenewswire.com/NewsRoom/AttachmentNg/b8da4d92-789b-4f0a-a1e2-2739af370155)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.